Clinical and economic aspects of the use of OneTouch glucose meters for the screening of diabetes mellitus

Diabetes is increasingly widespread in the Russian Federation. It is a severe chronic disease that both independently reduces quality of life and causes exacerbation of other pathologies. This makes evaluation of quality of diabetes management and understanding of clinical and economic properties of various technologies used to screen blood glucose levels, including portable blood glucose meters. Previously there already were clinical-economic evaluations of blood glucose meters within context of Russian Federation but they have not included modern high-precision equipment, thus ensuring attractiveness of current research effort into HTA of modern blood glucose meters that accounts for real life hospital practice.
Goal. To assess the clinic-economic properties of modern blood glucose portable measurement systems of OneTouch family and the real-world practics of their use in Russian healthcare facilities.
Methodology. The research was performed from the perspective of the Russian healthcare system. Target population was represented by a virtual cohort of 100 patients. Only direct costs were accounted for, specifically all costs caused by consumables involved in operating multifunctional laboratory complexes and all consumables involved in operating portable glucose meters. Employee salaries were also included (accounting for number of personnel involved in different procedures as based on a real clinical practice survey performed as part of this research). Since it is known that modern, standard-compliant portable glucose meters have an accuracy that is more than sufficient for routine screening, cost minimization analysis was used for assessment of economic effects when comparing different approaches to organizing glucose level screening.
Research results. The survey during this research effort has indicated that not all medical facilities utilize “tandem usage” of multifunction laboratory complexes and portable glucose meters, however, such “tandem use” is the most widespread approach to organizing blood glucose screening. Cost minimization analysis has demonstrated that “tandem usage” is also the most economically attractive approach and results in cost savings for the medical facility.
Conclusions. Current research effort which included cost analysis and cost minimization analysis has demonstrated that “tandem usage” approach which involves combined use of both multifunction laboratory complexes and portable glucose meter systems has substantial economic advantage (over 60 % for analysis with 5 year time horizon). Multiple sensitivity analyses have confirmed robustness of this result. This research further establishes the importance of communicating advantages of modern portable glucose meters to healthcare organizers since this technology is not only clinically rational but also economically optimal.

1. Анциферов М. Б., Демидов Н. А., Калашникова М. Ф., Духарева О. В., Викулова О. К., Шестакова М. В. Динамика основных эпидемиологических показателей у пациентов с сахарным диабетом, проживающих в Москве (2013–2018). Сахарный диабет. 2020;23(2):113–24. [Antsiferov M. B., Demidov N. A., Kalashnikova M. F., Duhareva O. V., Vikulova O. K., Shestakova M. V. The dynamics of the main epidemiological indicators among living in Moscow patients with diabetes mellitus (2013–2018). Diabetes mellitus. 2020;23(2):113–24. (In Russ).]. doi: 10.14341/DM11374

2. Ohkuma T, Komorita Y, Peters SAE, Woodward M. Diabetes as a risk factor for heart failure in women and men: a systematic review and meta-analysis of 47 cohorts including 12 million individuals. Diabetologia. 2019;62(9):1550–60. doi: 10.1007/s00125-019-4926-x

3. Chase-Vilchez AZ, Chan IHY, Peters SAE, Woodward M. Diabetes as a risk factor for incident peripheral arterial disease in women compared to men: a systematic review and meta-analysis. Cardiovasc Diabetol. 2020;19(1):151. doi: 10.1186/s12933-020-01130-4

4. Deischinger C, Dervic E, Leutner M, Kosi-Trebotic L, Klimek P, Kautzky A, Kautzky-Willer A. Diabetes mellitus is associated with a higher risk for major depressive disorder in women than in men. BMJ Open Diabetes ResCare. 2020;8(1):e001430. doi: 10.1136/bmjdrc-2020-001430

5. Klonoff DC. Improved Outcomes from Diabetes Monitoring: The Benefits of Better Adherence, Therapy Adjustments, Patient Education, and Telemedicine Support. J Diabetes Sci Technol. 2012;6(3);486–90. doi: 10.1177/193229681200600301

6. Moser EG, Crew LB, Garg SK. Role of continuous glucose monitoring in diabetes management. Avances en Diabetología. 2010;26(2):73–8. doi: 10.1016/S1134-3230(10)62002-9

7. Клинические рекомендации. Алгоритмы специализированной медицинской помощи больным сахарным диабетом / под редакцией И. И. Дедова, М. В. Шестаковой, А. Ю. Майорова. — 9-й выпуск (дополненный). — М., 2019. — 2016 с. [Clinical recommendations. Standards of specialized diabetes care. Edited by Dedov II, Shestakova MV, Mayorov AYu. 9th Edition (revised). Moscow, 2019. (In Russ).]. doi: 10.14341/DM221S1

8. Setford S, Phillips S, Grady M. Evidence From a Long-Term, Systematic Post-Market Surveillance Program: Clinical Performance of a HematocritInsensitive Blood Glucose Test Strip. J Diabetes Sci Technol. 2021;15(1):67– 75. doi: 10.1177/1932296819826968

9. Le HT, Rice MJ. Several Steps Forward: A New Meter for Multiple Patient Use. J Diabetes Sci Technol. 2013;7(2):399–401. doi: 10.1177/193229681300700216

10. Куликов А. Ю., Бабий В. В. Фармакоэкономический анализ использования глюкометра «Контур ТС» в лечении больных сахарным диабетом. Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология. 2013;6(4):53–8. [Kulikov AU, Babiy VV. Pharmacoeconomic analysis of blood glucose meter Contour TS in diabetes treatment. Farmakoekonomika. Sovremennaya farmakoekonomika i farmakoepidemiologiya. 2013;6(4):53–8. (In Russ).].

11. Портал Информационной Поддержки Работников ЛПУ «ЗДРАВ» [Электронный ресурс]. [Portal Informacionnoj Podderzhki Rabotnikov LPU “ZDRAV” [Electronic resource]. (In Russ).]. URL: https://www.zdrav.ru/articles/4293661125-19-m10-21-zarplata-medsestry (дата обращения: 22.04.2021).

12. Федеральная служба государственной статистики [Электронный ресурс]. [Federal State Statistics Service [Electronic resource]. (In Russ).]. URL: http://www.gks.ru/ (дата обращения: 29.04.2021).

13. ГОСТ Р ИСО 15197-2015 [Электронный ресурс]. [GOST R ISO 15197-2015. [Electronic resource]. (In Russ).]. URL: http://www.gks.ru/. URL: https://pdf.standartgost.ru/catalog/Data2/1/4293764/4293764268.pdf (дата обращения: 09.09.2021).

14. Постановление Правительства РФ от 01.01.2002 № 1 «О классификации основных средств, включаемых в амортизационные группы». [Resolution of the Government of the Russian Federation of 01.01.2002 N 1 “O klassifikacii osnovnyh sredstv, vklyuchaemyh v amortizacionnye gruppy.” (In Russ).].

15. Отраслевой стандарт «Клинико-экономические исследования. Общие положения»: приказ Минздрава РФ от 27.05.2002 № 163 вместе с ОСТ 91500.14.0001-2002. [Industry Standard «Kliniko-ekonomicheskie issledovaniya. Obshchie polozheniya»: Order of the Ministry of Health of the Russian Federation dated 27.05.2002 No. 163 together with OST 91500.14.0001-2002. (In Russ).].

16. Включение лекарственных препаратов в ограничительные перечни: пошаговый алгоритм [Электронный ресурс] / под общ. ред. Белоусова Д. Ю., Зырянова С. К. — Москва: Издательство ОКИ, 2019. — 252 c. — ISBN 978-5-4465-2555-3. [Inclusion of medicines in restrictive lists: a step-by-step algorithm [Electronic resource] / under the general ed. by Belousov DYu, Zyryanov SK. Moscow: Publishing OKI. (In Russ).]. URL: https://clck.ru/Y6Jqb.

17. Белоусов Ю. Б., Белоусов Д. Ю. Основы фармакоэкономических исследований: учебное пособие. – М.: Национальный фонд содействия научным и клиническим исследованиям при РГМУ, 2000. [Belousov YuB, Belousov DYu. Osnovy farmakoekonomicheskih issledovanij: uchebnoe posobie. Moscow: Nacional’nyj fond sodejstviya nauchnym i klinicheskim issledovaniyam pri RGMU, 2000. (In Russ).].